NeuroPace (NPCE) Income from Continuing Operations (2020 - 2026)
NeuroPace (NPCE) posted quarterly Income from Continuing Operations of 21967000.0 for Q1 2026, down 235.17% year-over-year from 16251463.82 in Q1 2025, and down 748.15% quarter-over-quarter from 2590000.0 in Q4 2025.
NeuroPace (NPCE) Income from Continuing Operations (2020 - 2026) Analysis & Trends
NeuroPace's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 21967000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 235.17% year-over-year to 21967000.0; the TTM figure through Mar 2026 stood at 51504000.0 (down 88.05% YoY), while the FY2025 annual figure was 36032000.0, up 62.79% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 21967000.0, down from 2590000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2405000.0 in Q4 2023, with the low at 21967000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 9018000.0 (2024), against an average of 9602176.47.
- The sharpest annual moves came in 2023 and 2026: Income from Continuing Operations surged 78.14% in 2023, then tumbled 235.17% in 2026.
- NeuroPace's Income from Continuing Operations stood at 11000000.0 in 2022, then soared by 78.14% to 2405000.0 in 2023, then tumbled by 210.94% to 7478000.0 in 2024, then soared by 65.37% to 2590000.0 in 2025, then tumbled by 748.15% to 21967000.0 in 2026.
- Business Quant data shows NPCE's Income from Continuing Operations at 21967000.0 in Q1 2026, 2590000.0 in Q4 2025, and 4985000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.20 Bn | 194.60 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 129.69 Bn | 126.21 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 120.14 Bn | 110.92 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn | 905.00 Mn |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.43 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.57 Bn | 32.62 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 34.09 Bn | 31.98 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.49 Bn | 23.17 Bn | 4.55 Bn | 1.04 Bn |
| 9 | Steris | 23.19 Bn | 22.70 Bn | 684.20 Mn | 201.00 Mn |
| 10 | NeuroPace | 479.51 Mn | 427.81 Mn | 18.91 Mn | -6.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.30 Mn |
| Mar 31, 2026 | -21.97 Mn |
| Dec 31, 2025 | -2.59 Mn |
| Sep 30, 2025 | -4.99 Mn |
| Jun 30, 2025 | -21.96 Mn |
| Mar 31, 2025 | -6.55 Mn |
| Dec 31, 2024 | -7.48 Mn |
| Sep 30, 2024 | -5.69 Mn |
| Jun 30, 2024 | -7.67 Mn |
| Mar 31, 2024 | -9.02 Mn |
| Dec 31, 2023 | -2.41 Mn |
| Sep 30, 2023 | -7.37 Mn |
| Jun 30, 2023 | -9.25 Mn |
| Mar 31, 2023 | -9.56 Mn |
| Dec 31, 2022 | -11.00 Mn |
| Sep 30, 2022 | -11.68 Mn |
| Jun 30, 2022 | -12.61 Mn |
| Mar 31, 2022 | -11.46 Mn |
| Dec 31, 2021 | -10.74 Mn |
| Sep 30, 2021 | -7.93 Mn |